European Neuropsychopharmacology最新文献

{"title":"Therapygenetics: Serotonin transporter gene polymorphism (5-HTTLPR) is associated with behavioral treatment response to virtual exposure therapy in patients with spider phobia","authors":"Elisabeth Schrammen ,&nbsp;Chiara Hilbrich ,&nbsp;Joscha Böhnlein ,&nbsp;Kati Roesmann ,&nbsp;Bettina Gathmann ,&nbsp;Martin J. Herrmann ,&nbsp;Markus Junghöfer ,&nbsp;Hanna Schwarzmeier ,&nbsp;Fabian R. Seeger ,&nbsp;Niklas Siminski ,&nbsp;Thomas Straube ,&nbsp;Heike Weber ,&nbsp;Ulrike Lueken ,&nbsp;Udo Dannlowski ,&nbsp;Katharina Domschke ,&nbsp;Miriam A. Schiele ,&nbsp;Elisabeth J. Leehr","doi":"10.1016/j.euroneuro.2025.07.002","DOIUrl":"10.1016/j.euroneuro.2025.07.002","url":null,"abstract":"<div><div>Identifying biomarkers predicting therapy outcomes before treatment holds great promise for advancing precision medicine. Genetic variants such as the serotonin transporter gene linked polymorphic region (<em>5-HTT</em>LPR) may be associated with response to cognitive behavioral therapy in anxiety disorders, albeit results so far are controversial. Contributing to the ongoing debate, we investigated whether treatment response to a highly standardized one-session virtual reality exposure therapy (VRET) was predicted by <em>5-HTT</em>LPR genotype. <em>N</em> = 194 patients with arachnophobia (spider phobia) were genotyped for <em>5-HTT</em>LPR and the functionally related single nucleotide polymorphism rs25531 and grouped into high- (LA/LA), and low-expression (S/S, S/LG, LG/LG, S/LA, LG/LA) genotype. At baseline, after VRET, and at a 6-month follow-up, participants underwent a standardized behavioral avoidance task (BAT) and the spider phobia questionnaire (SPQ) to assess symptom severity. Chi-square tests revealed a significant association between <em>5-HTT</em>LPR/rs25531 and behavioral treatment outcome, that remained significant at the 6-month follow-up. No association was found between genotype and self-reported symptom severity measured with the SPQ. Our results support the idea that while LA/LA genotype carriers might benefit from highly standardized treatment, lower <em>5-HTT</em> expression may convey risk to poorer treatment response, likely necessitating more tailored psychotherapeutic interventions to promote sufficient response.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"98 ","pages":"Pages 46-48"},"PeriodicalIF":6.1,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144631537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extrapyramidal symptoms as early clinical predictors in first-episode schizophrenia and schizophreniform disorder: findings from the OPTiMiSE trial","authors":"Joaquín Galvañ ,&nbsp;José Suárez-Campayo ,&nbsp;Miriam Ayora ,&nbsp;Santiago Gil ,&nbsp;Inge Winter-van Rossum ,&nbsp;Gregor Berger ,&nbsp;Stefan Leucht ,&nbsp;René S. Kahn ,&nbsp;Celso Arango ,&nbsp;Covadonga M. Díaz-Caneja","doi":"10.1016/j.euroneuro.2025.06.007","DOIUrl":"10.1016/j.euroneuro.2025.06.007","url":null,"abstract":"<div><div>Extrapyramidal symptoms (EPS) may occur as a primary feature in patients with first-episode psychosis with no or brief exposure to antipsychotics (AP). We aimed to analyse the prevalence of EPS in naïve and <em>quasi</em>-naïve first episode schizophrenia spectrum disorders (FES), their demographic and clinical correlates at baseline, and their association with clinical outcomes during follow-up. We analysed data from the OPTiMiSE trial, Phase 1 (<em>n</em> = 481 participants with FES, aged 18–40). The presence of EPS was defined as a score on the neurological side effects subscale of the UKU ≥ 1. We compared groups with and without baseline EPS in demographic, clinical and functional measures, and performed logistic and linear regressions models to analyse the associations between baseline EPS and clinical outcomes at follow-up. The prevalence of EPS at baseline was 30 % and was higher in women. There were no differences between AP-naïve or <em>quasi</em>-naïve participants. Participants with EPS showed a higher rate of depressive symptoms and suicidality at baseline. The fully adjusted models showed an association between the presence of EPS at baseline and more severe depressive, positive, negative, general and total symptoms, increased suicidality, and poorer subjective wellbeing and functionality at follow-up. Our findings support EPS as a primary feature of schizophrenia and suggest that early onset EPS (after no or minimal AP exposure) may point to a FES subgroup with poorer clinical prognosis. This suggests the role of EPS as an early marker of poor outcome, with the potential to guide targeted interventions in FES.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"98 ","pages":"Pages 35-45"},"PeriodicalIF":6.1,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144611872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emotional cognition in patients with borderline personality disorder and patients with bipolar disorder type II: Evidence for transdiagnostic and differential diagnostic differences?","authors":"Emilie Hestbaek ,&nbsp;Johanna Kølle Pedersen ,&nbsp;Hanne Lie Kjærstad ,&nbsp;Kirsten Rosenkrantz Grage ,&nbsp;Lars Vedel Kessing ,&nbsp;Sebastian Simonsen ,&nbsp;Kamilla Miskowiak","doi":"10.1016/j.euroneuro.2025.06.010","DOIUrl":"10.1016/j.euroneuro.2025.06.010","url":null,"abstract":"<div><h3>Introduction</h3><div>Distinguishing borderline personality disorder (BPD) from bipolar disorder type II (BD-II) is challenging due to overlapping symptoms, often leading to misdiagnosis and suboptimal treatment. This study explored transdiagnostic and diagnostic differences in emotional cognition between patients with BPD, patients with BD-II and healthy controls (HC).</div></div><div><h3>Experimental procedures</h3><div>The sample included 35 patients with BPD, 35 with BD-II in remission, and 35 HC. Emotional cognition was assessed with virtual reality (VR) and the Facial Expression Recognition Task. Participants completed questionnaires regarding occupational and social functioning, quality of life, and childhood trauma. Transdiagnostic differences were explored by comparing each patient group to HC, and diagnostic differences were examined between BPD and BD-II. Regression analyses evaluated the impact of childhood trauma on emotional cognition.</div></div><div><h3>Results</h3><div>Transdiagnostically, patients showed poorer emotion regulation in negative VR scenarios compared to HC, but there were no differences in emotional face processing. Differential diagnostically, patients with BPD were slower at identifying emotional faces than those with BD-II, with trends towards lower accuracy. No significant differences were observed between patients with BPD and patients with BD-II in VR scenarios. Across participants, childhood trauma predicted blunted emotion ratings and slower facial emotion recognition.</div></div><div><h3>Discussion</h3><div>Impaired emotion regulation may serve as a transdiagnostic biomarker for BPD and BD-II, while slower emotion recognition may distinguish BPD from BD-II. Across participants, childhood trauma predicted blunted emotion ratings and slower facial emotion recognition, underscoring its lasting impact.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"98 ","pages":"Pages 13-21"},"PeriodicalIF":6.1,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144597380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic variants of uncertain significance in psychiatry and the potential for confusion among patients and clinicians alike","authors":"Mark Ainsley Colijn","doi":"10.1016/j.euroneuro.2025.06.009","DOIUrl":"10.1016/j.euroneuro.2025.06.009","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"98 ","pages":"Pages 22-23"},"PeriodicalIF":6.1,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144597382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inflammation–neurotrophin interplay and depression outcomes: authors’ reply","authors":"Chan-Yeong Cho ,&nbsp;Hee-Ju Kang ,&nbsp;Ju-Wan Kim,&nbsp;Sung-Wan Kim,&nbsp;Jae-Min Kim","doi":"10.1016/j.euroneuro.2025.06.008","DOIUrl":"10.1016/j.euroneuro.2025.06.008","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"98 ","pages":"Pages 24-25"},"PeriodicalIF":6.1,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144596460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical predictors of treatment resistant depression","authors":"Alessandro Serretti ,&nbsp;Siegfried Kasper ,&nbsp;Lucie Bartova ,&nbsp;Joseph Zohar ,&nbsp;Daniel Souery ,&nbsp;Stuart Montgomery ,&nbsp;Panagiotis Ferentinos ,&nbsp;Dan Rujescu ,&nbsp;Alexander Kautzky ,&nbsp;Francesco Attanasio ,&nbsp;Raffaella Zanardi ,&nbsp;Chiara Fabbri ,&nbsp;Bernhard T Baune ,&nbsp;Raffaele Ferri ,&nbsp;Julien Mendlewicz","doi":"10.1016/j.euroneuro.2025.06.011","DOIUrl":"10.1016/j.euroneuro.2025.06.011","url":null,"abstract":"<div><div>Despite advances in the treatment of major depressive disorder (MDD) yet a substantial proportion of patients fail to achieve remission and instead develop treatment-resistant depression (TRD). Identifying robust clinical predictors of response is essential for early, personalized interventions.</div><div>We analyzed a large, multicenter sample (<em>N</em> = 2953) from the Group for the Study of Resistant Depression (GSRD) project, which included previously studied cohorts (TRD I–III) and a newly recruited cohort (TRD IV, <em>N</em> = 294). Patients were categorized as responders, non-responders, or TRD. Sociodemographic and clinical variables, including current and retrospective MADRS items, were used to train an XGBoost classifier. Primary outcomes were the multi-class metrics area under the curve (AUC), accuracy, and F1-scores.</div><div>Previously reported predictors were mainly confirmed in the new TRD IV sample. The XGBoost model showed a mean ROC AUC of 0.80 and an accuracy of 61 %, significantly above chance. Misclassification was more frequent among responders versus non-responders, while TRD was predicted most accurately (precision=0.73; recall=0.73). Measures of illness chronicity, such as duration of current episode, duration of disease lifetime, number of hospitalizations, and number of depressive episodes, as well as severity features, BMI and level of functioning were among the most important predictors. Secondary analyses using earlier cohorts to train and the new TRD IV sample to test confirmed stable performance metrics.</div><div>Our findings highlight the central role of chronicity indicators, severity measures and functioning in predicting antidepressant response and TRD. Future work should include prospective validation and integration of biomarker data to further enhance predictive power.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"98 ","pages":"Pages 26-34"},"PeriodicalIF":6.1,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144604763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Orexin receptor antagonists: Potential as novel antidepressants and anxiolytics","authors":"Harry A. Fagan ,&nbsp;David S. Baldwin","doi":"10.1016/j.euroneuro.2025.07.003","DOIUrl":"10.1016/j.euroneuro.2025.07.003","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"98 ","pages":"Pages 11-12"},"PeriodicalIF":6.1,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144597381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Semaglutide suppresses cocaine taking, seeking, and cocaine-evoked dopamine levels in the nucleus accumbens","authors":"Cajsa Aranäs ,&nbsp;Antonia Caffrey ,&nbsp;Christian E. Edvardsson ,&nbsp;Heath D. Schmidt ,&nbsp;Elisabet Jerlhag","doi":"10.1016/j.euroneuro.2025.07.001","DOIUrl":"10.1016/j.euroneuro.2025.07.001","url":null,"abstract":"<div><div>Currently, no pharmaceutical treatments exist for cocaine use disorder, which is characterized by dysregulated motivation, intense drug craving, compulsive drug-seeking behavior, and relapse during abstinence. While short-acting glucagon-like peptide-1 receptor (GLP-1R) reduces cocaine-related behaviors, its impact is limited by low affinity towards GLP-1R. Semaglutide may be beneficial in this context as it is long-acting with greater potency and affinity for the GLP-1R. Its superiority is substantiated in studies on alcohol and alcohol use disorder (AUD) as it profoundly reduces alcohol intake in animals and patients with AUD, whereas exendin-4 (Ex4) slightly reduces alcohol intake in rats, whereas it does not alter alcohol intake in AUD patients. However, it remains to be explored whether its beneficial effects extend to more complex cocaine-related behaviors, the aim of the present study. Using the cocaine self-administration paradigm in male rats, we tested the efficacy of different doses of semaglutide to reduce voluntary cocaine taking, the motivation to consume cocaine, and the reinstatement of cocaine-seeking behavior. Furthermore, we explored the effects of semaglutide on cocaine-evoked dopamine levels in the nucleus accumbens (NAc). Semaglutide decreased cocaine self-administration, the motivation to consume cocaine, and cocaine reinstatement in male rats. Moreover, semaglutide attenuated cocaine-induced elevation of dopamine levels in mice and rats. Additionally, neither of the tested doses altered kaolin intake, a measurement of malaise, in cocaine-experienced rats. These findings further support the role of GLP-1R in cocaine taking and imply that semaglutide should be tested as a candidate for treating cocaine use disorder.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"98 ","pages":"Pages 1-10"},"PeriodicalIF":6.1,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144596328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of psilocybin therapy versus escitalopram on cognitive bias: A secondary analysis of a randomized controlled trial","authors":"Jessica Henry ,&nbsp;Bruna Giribaldi ,&nbsp;David J. Nutt ,&nbsp;David Erritzoe ,&nbsp;Robin Carhart-Harris ,&nbsp;Taylor Lyons","doi":"10.1016/j.euroneuro.2025.06.003","DOIUrl":"10.1016/j.euroneuro.2025.06.003","url":null,"abstract":"<div><h3>Background</h3><div>Patients with Major Depressive Disorder (MDD) have more dysfunctional attitudes than healthy individuals and these pessimistic biases are correlated with depression severity. Psilocybin has demonstrated sustained remission in depression.</div></div><div><h3>Methods</h3><div>Secondary analysis of a two-arm randomized controlled trial assessing the effect of psilocybin therapy versus escitalopram on ‘maladaptive’ cognitive biases relevant to the construct of depression. Primary outcomes were post-treatment changes in biases at six weeks compared with baseline, as measured using three validated psychological scales.</div></div><div><h3>Findings</h3><div>Fifty-nine MDD patients were randomly allocated to the psilocybin (<em>n</em> = 30) or escitalopram (<em>n</em> = 29) groups. Self-reported optimism showed a large increase six-weeks after psilocybin treatment (<em>M_diff</em>=6·63 <em>p</em> &lt; 0·0001; 95 % <em>CI</em> [4·06, 9·20], <em>d</em> = 1·1), whereas there was no change following escitalopram (<em>M_diff</em>=1·52, <em>p</em> = 0·205; 95 % <em>CI</em> [-0·59, 3·62], <em>d</em> = 0·4). Behavioral results found that patients were more optimistic about desirable life events after psilocybin treatment (<em>M_diff</em>=0·16, <em>p</em> = 0·0002; 95 % <em>CI</em> [0·08, 0·23], <em>d</em> = 1·1), but they were also less pessimistic about negative life events after escitalopram treatment (<em>M_diff</em>=0·07, <em>p</em> = 0·018; 95 % <em>CI</em> [0·01, 0·13], <em>d</em> = 0·5). We found improvements in all three domains of dysfunctional attitudes following psilocybin treatment: achievement (<em>M_diff</em>=10·37, <em>p</em> &lt; 0·0001; 95 % <em>CI</em> [6·38, 14·53], <em>d</em> = 1·0); dependency (<em>M_diff</em>=7·97, <em>p</em> &lt; 0·0001; 95 % <em>CI</em> [4·00, 11·93], <em>d</em> = 0·9) and self-control (<em>M_diff</em>=6·40, <em>p</em> = 0·0006; 95 % <em>CI</em> [2·60, 10·20], <em>d</em> = 0·8)), whereas only the achievement domain improved after escitalopram (<em>M_diff</em>=4·10, <em>p</em> = 0·005; 95 % <em>CI</em> [1·35, 6·86], <em>d</em> = 0·6).</div></div><div><h3>Interpretation</h3><div>These results suggest that two high-dose sessions with psilocybin therapy are superior to a six-week daily course of a selective serotonin-reuptake inhibitor antidepressant, in remediating negative cognitive biases in depression.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"97 ","pages":"Pages 51-60"},"PeriodicalIF":6.1,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144338468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcriptome meta-analysis of valproic acid exposure: A new approach in human brain organoids","authors":"João Vitor Pacheco Foletto ,&nbsp;Fernanda Sales Luiz Vianna ,&nbsp;Lavinia Schuler-Faccini ,&nbsp;Thayne Woycinck Kowalski","doi":"10.1016/j.euroneuro.2025.05.008","DOIUrl":"10.1016/j.euroneuro.2025.05.008","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"97 ","pages":"Pages 38-39"},"PeriodicalIF":6.1,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144322484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}